Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?

Pfizer appears undervalued with a 6.8% dividend yield and low P/E ratio of 8.5x, but investors remain skeptical due to negative revenue growth over three years and upcoming patent cliffs, particularly for its blockbuster drug Eliquis. However, the company's deep pipeline in weight management and oncology, including promising candidates like MET-097i and PF-4404, could drive significant recovery if clinical trials succeed, making it potentially attractive for long-term income investors.

07/31/2026, 3:09 PM • The Motley Fool

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been recognized in The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The recognition highlights the company's achievements in advancing innovative cancer therapies, including the commercialization of olverembatinib and lisaftoclax, with multiple global Phase III clinical trials underway.

07/26/2026, 7:30 PM • GlobeNewswire

Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried.

Pfizer's 6.8% dividend yield significantly exceeds market averages, raising concerns about sustainability. However, management remains committed to maintaining and growing the dividend, as evidenced by Q1 2026 earnings presentations. The company generated sufficient operating cash flow to cover dividend payments and maintain a higher cash balance, supported by $11.3 billion in long-term investments. While Pfizer faces industry headwinds including patent expirations and delays in GLP-1 drug development, analysts suggest the company has the financial capacity to sustain its dividend through this challenging period.

07/25/2026, 8:15 AM • The Motley Fool

Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell.

The article recommends three dividend stocks suitable for long-term buy-and-hold investors: Pfizer, which is developing new blockbuster drugs and entering the obesity drug market; Coca-Cola, with 64 years of consecutive dividend increases and a resilient business model; and Brookfield Renewable, which offers recurring income from renewable energy assets with 5-9% annual dividend growth targets.

07/22/2026, 11:23 AM • The Motley Fool

PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight

A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late-stage development and 30+ in mid and early stages. Recent developments include FDA breakthrough designations and positive clinical trial results for combination therapies.

07/21/2026, 1:00 PM • GlobeNewswire

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?

Pfizer is positioning itself as a contender in the rapidly growing $100 billion weight-loss drug market through its acquisition of Metsera and development of promising GLP-1 candidates like MET-097i, which showed strong efficacy with potential monthly dosing. However, the company faces stiff competition from Eli Lilly and Novo Nordisk, who currently lead the market with more advanced triple agonist drugs. While Pfizer may not dominate the space, it is well-positioned to be a significant player, and the company has other growth drivers including oncology pipeline and a high dividend yield of 6.9%.

07/20/2026, 3:15 AM • The Motley Fool

Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now

Pfizer's stock has fallen over 50% from late 2021 highs, pushing its dividend yield to a historically high 6.9%. While the company faces normal industry headwinds including upcoming patent expirations and disappointing new drug development, management remains committed to protecting the dividend. The company is taking steps to address challenges, including acquiring a weight-loss drug candidate after dropping its own GLP-1 drug. More aggressive dividend investors may find Pfizer's valuation compelling despite risks.

07/19/2026, 7:15 AM • The Motley Fool

Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff?

Pfizer's attractive 7% dividend yield masks significant risks as the company faces a patent cliff with major drugs losing protection in 2027-2028. With a dividend payout ratio over 130% and limited new drug candidates in the pipeline, investors are concerned about the sustainability of the dividend. However, the company has cash reserves and debt options to maintain payments, and management has prioritized dividend preservation.

07/18/2026, 9:15 AM • The Motley Fool

Bioinformatics Collaboration and Licensing Deals 2019-2026 | Compare Upfronts, Milestones, and Royalties for 1,230+ Deals

ResearchAndMarkets.com released a comprehensive report analyzing 1,230+ bioinformatics collaboration and licensing deals from 2019-2026, providing detailed benchmarking of upfronts, milestones, and royalty structures. The report serves as a reference for understanding how partnerships are structured in data-driven and platform-based transactions across the bioinformatics industry.

07/17/2026, 5:54 AM • GlobeNewswire

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

07/15/2026, 11:00 AM • GlobeNewswire

Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments Accelerates

The global oral obesity therapies market is projected to grow from $4.32 billion in 2026 to $6.32 billion by 2030, with a compound annual growth rate of 9.9%. The market expansion is driven by increasing demand for GLP-1 treatments, combination therapies, personalized metabolic treatments, and telehealth-enabled prescribing. Key opportunities include oral GLP-1 agonists, next-generation incretin drugs, and convenient non-injectable options for obesity management.

07/15/2026, 4:15 AM • GlobeNewswire

Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?

Pfizer's 7.1% dividend yield is the highest in the S&P 500, more than six times the average, raising concerns about sustainability. While the dividend currently appears safe with the company undergoing cost-cutting restructuring, earnings provide limited buffer with diluted per-share profit of $0.47 barely exceeding the quarterly dividend of $0.43. The stock trades at a low valuation of 8x estimated future earnings, potentially making it an underrated income option for investors willing to monitor it closely, though patent cliffs and future sales challenges pose risks.

07/14/2026, 10:24 AM • The Motley Fool

3 High-Yield Dividend Stocks Paying 5% or More That Are Worth Buying Now

The article highlights three high-yield dividend stocks with strong track records: Altria Group (MO) with a 5.91% yield and 57 years of consecutive dividend increases, Realty Income (O) offering 5.12% monthly dividends with 32 years of growth since going public, and Pfizer (PFE) yielding 7.12% despite post-COVID challenges. Each stock is positioned as a reliable income generator with potential for steady long-term returns.

07/12/2026, 3:25 AM • The Motley Fool

NCLA to Fifth Circuit: Revive Suit Against Gov’t-Led Censorship of Covid Vaccine-Injured Americans

The New Civil Liberties Alliance filed an appeal with the Fifth Circuit Court of Appeals challenging a district court's dismissal of a lawsuit alleging the Biden Administration orchestrated a censorship campaign targeting vaccine-injured individuals on social media. The case involves clients who suffered serious injuries or losses following COVID-19 vaccination and were censored when sharing their experiences online. NCLA argues the district court misapplied jurisdiction standards and Supreme Court precedent in dismissing the civil rights conspiracy claim.

07/08/2026, 6:38 PM • GlobeNewswire

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.

07/08/2026, 7:28 AM • The Motley Fool